Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a significant expansion of managed Medicare coverage for TONMYA (cyclobenzaprine HCl sublingual tablets), adding approximately 9 million Medicare beneficiaries effective January 1, 2027. This agreement, combined with previously announced commercial coverage and broad Medicaid availability, brings TONMYA's pharmacy coverage to approximately 145 million covered lives, or 46% of the U.S. covered market. Discussions with additional commercial and Medicare payers are ongoing.
Following the expanded coverage and positive launch metrics, Tonix plans to add 50 sales representatives by mid-third quarter 2026, increasing its commercial sales force to approximately 150 people. The company is also expanding marketing and medical affairs initiatives to increase awareness of TONMYA as a first-in-class, non-opioid treatment option for fibromyalgia.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA, the company's recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra.
Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
For more information, visit the company's newsroom at https://ibn.fm/TNXP.
